Table 4.
Comparison of areas of consensus achieved (≥75% agreement) between the ideal‐world and the real‐world settings at the MyAPCCC 2018.
| No. | Statements | % Agreement | |
|---|---|---|---|
| Ideal‐world | Real‐world | ||
| Management of CNPC | |||
| 1. | ADT and abiraterone as upfront therapy in mCNPC (Q41) | 86 | 27 |
| 2. | ADT alone in CNPC | ||
| De novo mCNPC with low‐volume disease (ideal‐world setting; Q43) | 86 | 100 | |
| Relapsed mCNPC after prior treatment for localized prostate cancer and with low‐volume disease (Q45) | 77 | 95 | |
| 3. | Docetaxel in addition to ADT in CNPC | ||
| Relapsed mCNPC after prior treatment for localized prostate cancer and with high‐volume disease (real‐world setting; Q44) | 36 | 81 | |
| Management of CRPC | |||
| 4. | First‐line CRPC | ||
| Abiraterone or enzalutamide for asymptomatic men without docetaxel for CNPC (Q50) | 90 | 36 | |
| Docetaxel for symptomatic men without docetaxel for CNPC (Q51) | 50 | 91 | |
| Abiraterone or enzalutamide for asymptomatic men with docetaxel for CNPC (Q52) | 95 | 59 | |
| 5. | Second‐line CRPC | ||
| Taxane for symptomatic men with mCRPC who had progressive disease as best response to first‐line abiraterone or enzalutamide (Q61) | 52 | 86 | |
| Abiraterone or enzalutamide in men with asymptomatic mCRPC and secondary (acquired) resistance (initial response followed by progression after use of first‐line abiraterone or enzalutamide (Q62) | 77 | 27 | |
| Taxane in men with symptomatic mCRPC and secondary (acquired) resistance (initial response followed by progression after use of first‐line abiraterone or enzalutamide (Q63) | 45 | 82 | |
| Abiraterone or enzalutamide for asymptomatic men with mCRPC progressing on or after docetaxel for mCRPC (without prior abiraterone or enzalutamide; Q64) | 100 | 68 | |
| 6. | Enzalutamide or apalutamide in addition to ADT in M0CRPC (Q86) | 100 | 27 |
| Use of osteoclast‐targeted therapy for SRE/SSE prevention for mCRPC | |||
| 7. | Indefinite osteoclast‐targeted treatment in mCRPC and bone metastases (Q89) | 82 | 27 |
ADT, androgen deprivation therapy; CNPC, castration‐naive prostate cancer; CRPC, castration‐resistant prostate cancer; mCNPC, metastatic CNPC; mCRPC, metastatic CRPC; Q, Question (see Supporting Information); SRE, skeletal‐related event; SSE, symptomatic skeletal event.